The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers
Background. Value assessments and treatment decision making typically focus on clinical endpoints, especially overall survival (OS). However, OS data are not always available, and surrogate markers may also have some value to patients. This study sought to estimate preferences for progression-free s...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-06-01
|
| Series: | MDM Policy & Practice |
| Online Access: | https://doi.org/10.1177/2381468319855386 |